Evidence map›Paper›PMID 23733191›Full record

ArticleThe Journal of biological chemistry2013

Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells.

Albert G Remacle, Sergey A Shiryaev, Vladislav S Golubkov, John N Freskos, Michael A Brown, Amolkumar S Karwa, Arati D Naik, Carol P Howard, Carolyn J Sympson, Alex Y Strongin

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Albert G RemacleSanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.
Sergey A Shiryaev
Vladislav S Golubkov
John N Freskos
Michael A Brown
Amolkumar S Karwa
Arati D Naik
Carol P Howard
Carolyn J Sympson
Alex Y Strongin
Mallinckrodt (United States) · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Proteolysis of Myelin as a Source of Neuropathic PainR01DE022757 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHUBAYEV, VERONICA · 2012 to 2022
$7.3M
METALLOPROTEINASES IN TUMOR NEOVASCULARIZATIONR01CA083017 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI STRONGIN, ALEX Y · 1999 to 2014
$3.8M
Biochemistry of MT1-MMP activation in malignancyR01CA157328 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI STRONGIN, ALEX Y · 2011 to 2015
$1.9M
NCI NIH HHS R01 CA083017NCI NIH HHS R01 CA157328NCI NIH HHS R01CA157328NCI NIH HHS R01CA83017NIDCR NIH HHS R01 DE022757NIDCR NIH HHS R01DE022757
6 · The paper itself

Abstract

Proteolytic activity of cell surface-associated MT1-matrix metalloproteinase (MMP) (MMP-14) is directly related to cell migration, invasion, and metastasis. MT1-MMP is regulated as a proteinase by activation and conversion of the latent proenzyme into the active enzyme, and also via inhibition by tissue inhibitors of MMPs (TIMPs) and self-proteolysis. MT1-MMP is also regulated as a membrane protein through its internalization and recycling. Routine immunohistochemistry, flow cytometry, reverse transcription-PCR, and immunoblotting methodologies do not allow quantitative imaging and assessment of the cell-surface levels of the active, TIMP-free MT1-MMP enzyme. Here, we developed a fluorescent reporter prototype that targets the cellular active MT1-MMP enzyme alone. The reporter (MP-3653) represents a liposome tagged with a fluorochrome and functionalized with a PEG chain spacer linked to an inhibitory hydroxamate warhead. Our studies using the MP-3653 reporter and its inactive derivative demonstrated that MP-3653 can be efficiently used not only to visualize the trafficking of MT1-MMP through the cell compartment, but also to quantify the femtomolar range amounts of the cell surface-associated active MT1-MMP enzyme in multiple cancer cell types, including breast carcinoma, fibrosarcoma, and melanoma. Thus, the levels of the naturally expressed, fully functional, active cellular MT1-MMP enzyme are roughly equal to 1 × 10(5) molecules/cell, whereas these levels are in a 1 × 10(6) range in the cells with the enforced MT1-MMP expression. We suggest that the reporter we developed will contribute to the laboratory studies of MT1-MMP and then, ultimately, to the design of novel, more efficient prognostic approaches and personalized cancer therapies.

Indexed as

AnimalsBinding, CompetitiveBlotting, WesternCell LineCell Line, TumorFluoresceinsFluorescent DyesHEK293 CellsHumansLiposomesMatrix Metalloproteinase 14MCF-7 CellsMicroscopy, FluorescenceMolecular ImagingMutationNeoplasms6-carboxyfluoresceinAlexa594FluoresceinsFluorescent DyesLiposomesMatrix Metalloproteinase 14Organic ChemicalsTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Breast CancerCancer BiologyDrug DeliveryEnzyme InhibitorsHydroxamate InhibitorsImagingLiposomesMatrix Metalloproteinase (MMP)MT1-MMPProtease Inhibitor

Identifiers

PMID23733191
PMCPMC3711321
OpenAlexW2032313792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.